Contribution: Industrial Research Assistance Program – Contributions to Firms
Resilience Biotechnologies Inc.
$2,103,150.00
Covid 19 Vaccine: Manufacturing Feasibility Study and Engineering Design
FY 2020-21 · 2020-11-01
Summary
The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other MCC projects and coronavirus vaccines that require insect cell/baculovirus expression systems and potentially adeno viral vectors. The two areas at Therapure’s current biomanufacturing facility that will be assessed to support pandemic vaccine manufacturing:
•Existing space within the facility
•Extension of the existing space with access to some of the existing utilities and all other systems such as Quality, Project Management, Finance and IT
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Mississauga|Mississauga, Ontario, Canada
Recipient Type
For-profit organization
Business Number
720950070
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-11-01 | 2020-21 | $2,103,150.00 |
| 2 | 2020-11-01 | 2020-21 | $2,103,150.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 123 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 123 jours.
Agreement End Date
2021-10-31
Agreement Number
959304
Agreement Start Date
2020-11-01
Agreement Title
Covid 19 Vaccine: Manufacturing Feasibility Study and Engineering Design
Agreement Title (French)
Vaccin contre la Covid-19 : Étude de faisabilité de fabrication et conception technique
Agreement Type
Contribution
Agreement Value
$2,103,150.00
Amendment Date
2021-06-28
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other MCC projects and coronavirus vaccines that require insect cell/baculovirus expression systems and potentially adeno viral vectors. The two areas at Therapure’s current biomanufacturing facility that will be assessed to support pandemic vaccine manufacturing:
•Existing space within the facility
•Extension of the existing space with access to some of the existing utilities and all other systems such as Quality, Project Management, Finance and IT
Description (French)
L'objectif de ce financement sera de soutenir une évaluation de faisabilité et une conception technique détaillée pour l'expansion de la capacité actuelle de Therapure en matière de culture de cellules de mammifères (CCM) en vue de soutenir le vaccin contre les coronavirus de VBI ainsi que d'autres projets CCM et vaccins contre les coronavirus qui nécessitent des systèmes d'expression de cellules d'insectes/baculovirus et potentiellement des vecteurs adénoviraux. Les deux domaines de l'actuelle installation de bioproduction de Therapure qui seront évalués pour soutenir la fabrication de vaccins contre la pandémie : • espace existant dans l'installation • extension de l'espace existant avec accès à certains des services publics existants et à tous les autres systèmes tels que la qualité, la gestion de projet, les finances et l'informatique.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Mississauga--Streetsville
Federal Riding (French)
Mississauga--Streetsville
Federal Riding Number
35063
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
720950070
Recipient City
Mississauga|Mississauga
Recipient Country
CA
Recipient Legal Name
Resilience Biotechnologies Inc.
Recipient Postal Code
L5N 8H9
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2020-2021-Q3-959304
